Promising Results from Study but More Work Needed for Healthcare Equity in Kenya

By Staff Writer

August 31, 2023

The African Health Markets for Equity (AHME) program has shown encouraging results in improving access to and quality of private health clinics in Kenya, according to a recent study. The research, a cluster randomised controlled trial, aimed to determine if the combination of social health insurance and management training could enhance healthcare services in the country.

The study revealed that AHME significantly impacted clinics, with the treatment group reporting a 26.0% increase in total clients and a 51.3% increase in National Hospital Insurance Fund (NHIF) clients. AHME also increased the likelihood of individuals having any form of health insurance, whether public or private.

However, the study did not find that AHME was successful in promoting pro-poor private healthcare. Poor households were significantly less likely to have health insurance, and there was no additional effect of AHME for this group. The study also found that AHME did not improve the quality of care for poor clients.

AHME focused on social health insurance as a mechanism for low-income households to receive high-quality healthcare at private or public clinics. The intervention encouraged and assisted private clinics to register under the NHIF scheme. This resulted in large effects on clinic registration and significant increases in the number of clients with public insurance served.

Despite these positive outcomes, more work is needed to improve insurance enrollment for poorer households. The study suggests that future research should focus on understanding the mechanisms through which increased clinic NHIF registration might increase demand-side insurance enrollment.

Reference url

Recent Posts

NICE health technology evaluations
Europe Health economic evaluations Health Equity and Access to Care Health Policy Healthcare decision modelling Healthcare systems HTA HTA policies 

Evolving NICE Health Technology Evaluations: Enhancing Patient Perspectives and Addressing Health Inequalities

João L. Carapinha

🌟 Are you ready to embrace a new era in health technology evaluations?

Our latest article dives into the recent updates from NICE regarding the incorporation of patient perspectives and tackling health inequalities in their health technology assessments. By exploring stakeholder feedback and proposed methodologies, we uncover a shift towards more inclusive and transparent evaluations that could reshape market access and reimbursement policies in the UK healthcare system.

Don’t miss out on these vital insights that could impact your understanding of healthcare value! Read the full article [here](https://www.nice.org.uk/process/pmg36/documents/consultation-comments-and-responses).

#SyenzaNews #HealthEconomics #MarketAccess

Canada Drug Agency Plan
Clinical guidelines and protocols Clinical Practice Cost-effectiveness analysis Drug pricing Evidence-based medicine Health Policy Healthcare access HTA North America Policymakers 

Canada Drug Agency Plan: Shaping the Future of Health Systems 2025-2030

João L. Carapinha

🚀 Are you ready to explore the future of healthcare in Canada?

The newly launched **Canada Drug Agency Plan** aims to redefine how we approach drug and health technology decisions, focusing on anticipation, innovation, and transformation to boost health outcomes for all Canadians. This five-year strategic initiative captures essential insights needed for a healthier nation amid evolving pharmaceutical policies.

Curious how this plan could impact the healthcare landscape? Dive into the full article to learn more!

#SyenzaNews #HealthcarePolicy #HealthTech #Innovation

hepatitis C treatment options
Asia Clinical Practice Clinical trials Diseases Global Infectious diseases Innovative Tech 

VIETNARMS Trial Unveils Innovative Hepatitis C Treatment Options

João L. Carapinha

🔍 Are you curious about the latest advancements in hepatitis C treatment options?

The groundbreaking VIETNARMS trial reveals that sofosbuvir-daclatasvir offers a comparable efficacy to sofosbuvir-velpatasvir while exploring innovative strategies that could reshape treatment accessibility and affordability. With cure rates exceeding 90%, these findings hold promise for improving outcomes, especially in underserved populations.

Dive into the full article to uncover how these developments could revolutionize hepatitis C care!

#SyenzaNews #globalhealth #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
PARTNER WITH US
schedule a meeting

SPEAK WITH US

+1 617 219 9400

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

WRITE US

inquiry2023@syenza.com

JOIN NEWSLETTER




SERVICES

QUICK LINKS

LINKEDIN
TWITTER
© 2025 Syenza™. All rights reserved.
Made with by Frogiez
schedule a meeting